| Company Name: |
Nantong QuanYi Biotechnology Co., Ltd
|
| Tel: |
0513-66337626 18051384581 |
| Email: |
sales@chemhifuture.com |
| Products Intro: |
Product Name:GSK248233A CAS:850665-21-3 Purity:98%HPLC Package:10mg,100mg,500mg,1g,2g,5g,10g,more
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:GSK248233A CAS:850665-21-3 Package:50mg;10mg
|
|
| | Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(dimethylamino)- Basic information |
| | Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(dimethylamino)- Chemical Properties |
| density | 1.41±0.1 g/cm3(Predicted) | | pka | 13.85±0.70(Predicted) |
| | Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(dimethylamino)- Usage And Synthesis |
| Uses | GSK248233A is a dual inhibitor of Fluc and VEGFR2 with IC50 of 1.03 μM and 2 nM, respectively. GSK248233A also shows activity against the AGC family. GSK248233A acts as a protein kinase inhibitor across ATP-dependent and -independent luciferases with potential implications for Fluc reporter assays[1]. | | References | [1] Dranchak P, et al. Profile of the GSK published protein kinase inhibitor set across ATP-dependent and-independent luciferases: implications for reporter-gene assays. PLoS One. 2013;8(3):e57888. DOI:10.1371/journal.pone.0057888 |
| | Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(dimethylamino)- Preparation Products And Raw materials |
|